Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


1 Acta Haematol
4 Am J Hematol
2 Ann Hematol
1 Biochem Pharmacol
1 Blood
2 BMC Cancer
3 Bone Marrow Transplant
1 Cancer Lett
3 Eur J Haematol
1 Exp Cell Res
1 Int J Hematol
1 J Immunol
2 J Natl Cancer Inst
2 Leuk Lymphoma
3 Leukemia
1 Oncogene
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. ARRIGO G, D'Ardia S, Audisio E, Cerrano M, et al
    Gilteritinib in isolated breast relapse of FLT3positive acute myeloid leukemia: a case report and review of literature.
    Acta Haematol. 2022 May 17. pii: 000524878. doi: 10.1159/000524878.
    PubMed         Abstract available

    Am J Hematol

  2. DINARDO CD, Lachowiez CA, Takahashi K, Loghavi S, et al
    Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2022 May 18. doi: 10.1002/ajh.26601.
    PubMed         Abstract available

  3. JONAS BA, Wei AH, Recher C, DiNardo CD, et al
    Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2022 May 14. doi: 10.1002/ajh.26600.

  4. GOTTLIEB DJ, Sutrave G, Jiang W, Avdic S, et al
    Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection and leukemia recurrence after allogeneic stem cell transplant.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26594.
    PubMed         Abstract available

  5. GORDON MJ, Ferrajoli A
    Unusual complications in the management of chronic lymphocytic leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26585.
    PubMed         Abstract available

    Ann Hematol

  6. ZENG Q, Xiang B, Liu Z
    Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Ann Hematol. 2022 May 16. pii: 10.1007/s00277-022-04863.
    PubMed         Abstract available

  7. PODVIN B, Guermouche H, Roynard P, Goursaud L, et al
    Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.
    Ann Hematol. 2022 May 13. pii: 10.1007/s00277-022-04861.

    Biochem Pharmacol

  8. GUO J, Liu K, Wang J, Jiang H, et al
    A rational foundation for micheliolide-based combination strategy by targeting redox and metabolic circuit in cancer cells.
    Biochem Pharmacol. 2022;200:115037.
    PubMed         Abstract available


  9. Genomic landscape of T-LGL leukemia.
    Blood. 2022;139:3100.

    BMC Cancer

  10. DING L, Szymczak JE, Evans E, Canepa E, et al
    Factors that contribute to disparities in time to acute leukemia diagnosis in young people: an in depth qualitative interview study.
    BMC Cancer. 2022;22:531.
    PubMed         Abstract available

  11. MUKRY SN, Shahni A, Zaidi U, Sultan Shamsi T, et al
    Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan.
    BMC Cancer. 2022;22:519.
    PubMed         Abstract available

    Bone Marrow Transplant

  12. DUQUE-AFONSO J, Finke J, Labopin M, Craddock C, et al
    Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2022 May 14. pii: 10.1038/s41409-022-01646.
    PubMed         Abstract available

  13. DANYLESKO I, Peczynski C, Labopin M, Polge E, et al
    Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
    Bone Marrow Transplant. 2022 May 13. pii: 10.1038/s41409-022-01695.
    PubMed         Abstract available

  14. JIANG JL, Chen M, Wang LN, Wan M, et al
    Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study.
    Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01643.

    Cancer Lett

  15. YE B, Sheng Y, Zhang M, Hu Y, et al
    Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
    Cancer Lett. 2022;538:215691.
    PubMed         Abstract available

    Eur J Haematol

  16. KEEGAN A, Dennington PM, Dhondy N, Mulligan SP, et al
    Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infection.
    Eur J Haematol. 2022;108:460-468.
    PubMed         Abstract available

  17. VU M, Degeling K, Thompson ER, Blombery P, et al
    Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
    Eur J Haematol. 2022;108:469-485.
    PubMed         Abstract available

  18. MURPHY P, Glavey S, Quinn J
    Intracranial haemorrhage in AML patients.
    Eur J Haematol. 2022;108:536.

    Exp Cell Res

  19. LIU H, Hussain Z, Xie Q, Yan X, et al
    Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax.
    Exp Cell Res. 2022 May 11:113192. doi: 10.1016/j.yexcr.2022.113192.
    PubMed         Abstract available

    Int J Hematol

  20. CAPRIA S, Trisolini SM, Diverio D, Minotti C, et al
    Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.
    Int J Hematol. 2022 May 13. pii: 10.1007/s12185-022-03370.
    PubMed         Abstract available

    J Immunol

  21. ROZOVSKI U, Veletic I, Harris DM, Li P, et al
    STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
    J Immunol. 2022 May 20. pii: jimmunol.2101105. doi: 10.4049/jimmunol.2101105.
    PubMed         Abstract available

    J Natl Cancer Inst

  22. ZHAO X, Qian M, Goodings C, Zhang Y, et al
    Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia.
    J Natl Cancer Inst. 2022 May 16. pii: 6586299. doi: 10.1093.
    PubMed         Abstract available

  23. RODWIN RL, Kairalla JA, Hibbitts E, Devidas M, et al
    Persistence of chemotherapy-induced peripheral neuropathy despite vincristine reduction in childhood b-acute lymphoblastic leukemia.
    J Natl Cancer Inst. 2022 May 12. pii: 6584828. doi: 10.1093.
    PubMed         Abstract available

    Leuk Lymphoma

  24. MAENG CV, Christiansen CF, Liu KD, Kamper P, et al
    Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
    Leuk Lymphoma. 2022 May 18:1-11. doi: 10.1080/10428194.2022.2074984.
    PubMed         Abstract available

  25. MACHHERNDL-SPANDL S, Vockenhuber T, Binder M, Weltermann A, et al
    Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 13:1-6. doi: 10.1080/10428194.2022.2068006.
    PubMed         Abstract available


  26. CURTISS BM, VanCampen J, Macaraeg J, Kong GL, et al
    PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
    Leukemia. 2022 May 19. pii: 10.1038/s41375-022-01594.
    PubMed         Abstract available

  27. HENGEVELD PJ, Ertem YE, Dubois JMN, Mellink CHM, et al
    Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21(R110).
    Leukemia. 2022 May 18. pii: 10.1038/s41375-022-01600.

  28. OLIVEIRA ML, Veloso A, Garcia EG, Iyer S, et al
    Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 May 17. pii: 10.1038/s41375-022-01590.
    PubMed         Abstract available


  29. GARZON R, Pichiorri F, Palumbo T, Visentini M, et al
    Correction to: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.
    Oncogene. 2022 May 11. pii: 10.1038/s41388-022-02351.

    PLoS One

  30. HIRANO S, Udagawa O
    Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
    PLoS One. 2022;17:e0268835.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.